MedTrace Logo

Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients

NCT02455271 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 438

Last updated 2018-09-07

No results posted yet for this study

Summary

To investigate the safety and efficacy of administration of eszopiclone for 6 months in insomnia participants.

Conditions

Interventions

DRUG

Eszopiclone

The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.

Sponsors & Collaborators

  • Eisai Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Akira Endo · Drug Fostering and Evolution Coordination Department, Corporate Medical Affairs Headquarters, Eisai Co., Ltd.

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-01
Primary Completion
2015-03-30
Completion
2015-12-22

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02455271 on ClinicalTrials.gov